Symptoms in patients on long‐term proton pump inhibitors: prevalence and predictors

Abstract

SUMMARY BackgroundSymptom control in primary care patients on long-term proton pump inhibitor (PPI) treatment is poorly understood.

The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS—A Cluster-Randomized Trial

“…Th is is a simple fi ve-item questionnaire that evaluates anxiety and depression, pain or discomfort, self-care, impact on usual activities, and mobility. It has been used in previous surveys of GERD in both primary ( 22,23 ) and secondary care ( 23 ), and has been correlated to refl ux symptom severity. To our knowledge, this is the fi rst randomized controlled trial to evaluate GERD pharmacological therapy that has used the EQ-5D.…”

Evolving issues in the management of reflux disease?

“…A recent cross-sectional survey of 726 patients on long-term PPIs (39% GERD) found that reflux symptoms persisted in 59% of patients [46]. Our recent meta-analysis of symptomatic GERD patients found that in about two-thirds of patients, reflux symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% patients still suffer symptoms 3 days later [47].…”

Ингибиторы Протонового Насоса

“…Ðåçóëüòàòû èññëåäîâàíèÿ ñðàâíèòåëü-íîé àêòèâíîñòè ðàçëè÷íûõ ÈÏÍ (ýçîìåïðàçîë, ëàí-ñîïðàçîë, ïàíòîïðàçîë, ðàáåïðàçîë) äîñòàòî÷íî ïðîòè-âîðå÷èâû [23]. Õîòÿ ÈÏÍ ÿâëÿþòñÿ ñàìûìè óñïåøíûìè èíãèáèòîðàìè êèñëîòîïðîäóêöèè, ó 59 % áîëüíûõ ÃÝÐÁ íà ôîíå äîëãîñðî÷íîé òåðàïèè ÈÏÍ íå èñ÷åçàþò ñèìïòîìû ðåôëþêñà [42]. Ïàöèåíòû ñ ÍÝÐÁ äåìîíñòðèðóþò ñàìóþ ìåäëåííóþ ñêîðîñòü ðàçâèòèÿ îòâåòà íà ÈÏÍ, è ýòîò îòâåò ñîñòàâëÿåò ëèøü îêîëî 50 -60 %.…”